AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
Lilly, J&J and AbbVie Hit New Highs
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
Is AbbVie a Buy After Its Purchase of Apogee?
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Why I Can't Stop Buying This Unstoppable Dividend Juggernaut
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
AbbVie's $11 Billion Immunology Bet
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching
AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
Nova Minerals redomiciles to US as Alaska gold and antimony work accelerates
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
G50 Corp strikes high-grade gold at first White Caps core hole in Nevada
3 Monster Stocks to Hold for the Next 10 Years
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
Empire Metals to host investor presentation on Pitfield progress
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Metals One builds 5.57% stake in newly listed Talon Resources
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Why AbbVie Stock Jumped Today
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
AbbVie Inc (ABBV) Shares Surge 6.2% -- What GF Score of 82 Tells Investors
AbbVie Inc. (ABBV) M&A Call Transcript
Nasdaq slides but Dow closes higher as investors ditch megacap tech
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Expand Immunology Pipeline
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?
Dow Jones still in the green but Nasdaq drops as hawkish Fed still looms
Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
AbbVie to acquire Apogee Therapeutics in $10.9B deal
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
5 Things to Know Before the Stock Market Opens
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
Breakfast News: AbbVie's $11 Billion Pounce
Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
Dow Jones opens higher but Nasdaq flat as hawkish Fed still looms
5 Dividend Stocks to Buy and Hold Forever